Recombinant Proteins iso9001 ISO13485
搜索
 > 【Angiopoietin-2】重组蛋白信息

Angiopoietin-2信息

英文名称:Angiopoietin-2
中文名称:血管生成素-2
靶点别称:ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
上市药物数量:0
临床药物数量:8
最高研发阶段:临床三期

Angiopoietin-2 分子别名

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Angiopoietin-2 分子背景

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Angiopoietin-2 参考文献

Angiopoietin-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
MEDI-3617 ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb 临床一期 Medimmune 卵巢癌, 黑色素瘤 详情
AMG-780 AMG-780 临床一期 安进 肿瘤 详情
LY-3127804 LY-3127804 临床二期 礼来制药 肺炎, 肿瘤, 新型冠状病毒肺炎 详情
Aflibercept/Nesvacumab REGN 910-3 临床二期 Regeneron Pharmaceuticals Inc 糖尿病黄斑水肿, 年龄相关性黄斑变性 详情
Trebananib AMG-386; 20060439 临床二期 安进, Takeda Pharmaceutical Co Ltd 卵巢癌, 实体瘤, 转移性上皮癌, 肾细胞癌, 直肠癌, 肾脏疾病, 结肠癌, 乳腺癌, 腹膜癌, 女性生殖系统癌症, 结直肠癌, 输卵管癌, 非小细胞肺癌, 转移癌, 胃肠道癌症 详情
BI-836880 BI-836880 临床一期 Ablynx 湿性黄斑变性, 鳞状细胞癌, 年龄相关性黄斑变性, 非小细胞肺癌 详情
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) 临床二期 罗氏 实体瘤, 肿瘤, 结直肠癌 详情
Faricimab RG-7716; RO-6867461 临床三期 罗氏 黄斑水肿, 糖尿病黄斑水肿, 湿性黄斑变性, 视网膜静脉阻塞, 糖尿病, 脉络膜新生血管化, 年龄相关性黄斑变性 详情

消息提示

请输入您的联系方式,再点击提交!

确定